Peritoneal Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peritoneal Cancer pipeline constitutes 60+ key companies continuously working towards developing 65+ Peritoneal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Peritoneal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Peritoneal Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peritoneal Cancer Market.

Some of the key takeaways from the Peritoneal Cancer Pipeline Report: https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Peritoneal Cancer treatment therapies with a considerable amount of success over the years.
• Peritoneal Cancer companies working in the treatment market are AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others, are developing therapies for the Peritoneal Cancer treatment
• Emerging Peritoneal Cancer therapies in the different phases of clinical trials are- Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others are expected to have a significant impact on the Peritoneal Cancer market in the coming years.
• In April 2025, Biocon Biologics obtained FDA approval for JobevneTM (bevacizumab-nwgd), a biosimilar of Avastin®, intended for intravenous administration. Jobevne is approved for the treatment of several cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and cancers of the fallopian tube, or primary peritoneum.
• In February 2025, Serac Healthcare reported positive feedback from the FDA after completing its End of Phase II Meeting for 99mTc-maraciclatide, a molecular imaging agent. This agent is being developed for use with SPECT-CT to help visualize and diagnose superficial peritoneal endometriosis (SPE) in women aged 16 and above.
• In February 2025, Alphamab Oncology has administered the first dose in its randomized Phase III JSKN003-306 trial, evaluating JSKN003, an anti-HER2 biparatopic antibody-drug conjugate (ADC), for the treatment of ovarian cancer.
• In December 2024, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that its Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) with chemotherapy, followed by maintenance with LYNPARZA® (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer, has met its primary endpoint of progression-free survival (PFS). The final analysis, conducted by an independent Data Monitoring Committee, showed that the KEYTRUDA plus LYNPARZA regimen significantly improved PFS compared to chemotherapy alone, demonstrating statistical and clinical significance.
• In October 2024, Oncoinvent administered the first dose in its Phase II clinical trial of Radspherin, an alpha-radiation therapy targeting peritoneal carcinomatosis resulting from ovarian cancer. This randomized, controlled trial aims to evaluate the efficacy and safety of the treatment. The study's primary objective is to compare progression-free survival between patients receiving Radspherin after surgery and those undergoing only pre-operative chemotherapy and surgery.

Peritoneal Cancer Overview
Peritoneal cancer is a rare type of cancer that occurs in the peritoneum, a thin layer of tissue that lines the abdomen and covers most of its organs. It is closely related to ovarian cancer and can cause similar symptoms. Peritoneal cancer can be primary, originating in the peritoneum itself, or secondary, spreading from other organs such as the ovaries, stomach, or colon. Symptoms may include abdominal pain or swelling, digestive issues, and unexplained weight loss. Treatment typically involves surgery, chemotherapy, and targeted therapies, depending on the cancer's origin and stage.

Get a Free Sample PDF Report to know more about Peritoneal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Peritoneal Cancer Drugs Under Different Phases of Clinical Development Include:
• Masitinib: AB Science
• Azenosertib: Zentalis Pharmaceuticals
• IMGN151: ImmunoGen
• Bevacizumab: Hoffmann-La Roche
• Nab-paclitaxel: Corcept Therapeutics
• 131 I-omburtamab: Memorial Sloan Kettering Cancer Center
• Catumaxomab: LintonPharm Co.,Ltd.
• Fulvestrant: M.D. Anderson Cancer Center
• Bevacizumab: ImmunoGen, Inc.
• Carboplatin: Merck Sharp & Dohme LLC
• MORAb-202: Bristol-Myers Squibb
• KAND567: Kancera AB
• ZEN003694: Haider Mahdi
• RC88: RemeGen Co., Ltd.
• HS-20089: Hansoh BioMedical
• navicixizumab: OncXerna Theraputics, Inc

Peritoneal Cancer Route of Administration
Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Peritoneal Cancer Molecule Type
Peritoneal Cancer Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Peritoneal Cancer Pipeline Therapeutics Assessment
• Peritoneal Cancer Assessment by Product Type
• Peritoneal Cancer By Stage and Product Type
• Peritoneal Cancer Assessment by Route of Administration
• Peritoneal Cancer By Stage and Route of Administration
• Peritoneal Cancer Assessment by Molecule Type
• Peritoneal Cancer by Stage and Molecule Type

DelveInsight's Peritoneal Cancer Report covers around 65+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Peritoneal Cancer product details are provided in the report. Download the Peritoneal Cancer pipeline report to learn more about the emerging Peritoneal Cancer therapies
https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Peritoneal Cancer Therapeutics Market include:
Key companies developing therapies for Peritoneal Cancer are - Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck & Co, AstraZeneca, Lee's Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Astex Pharmaceuticals, APIM Therapeutics, Celsion, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, Alkermes, Zenith Epigenetics, Sutro Biopharma, K-Group Beta, Bio-Path Holdings, Celldex Therapeutics, Rhizen Pharmaceuticals, Shattuck Labs, Inc., SELLAS Life Sciences Group, LIPAC oncology, Oncoinvent AS, Mereo Biopharma, Solasia Pharma, Mersana Therapeutics, Zentalis Pharmaceuticals, Lumicell Inc., Avenge Bio, and others.

Peritoneal Cancer Pipeline Analysis:
The Peritoneal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
• Peritoneal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peritoneal Cancer drugs and therapies
https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Peritoneal Cancer Pipeline Market Drivers
• Advancements in treatment, increasing Incidence, government Initiatives, collaborative Efforts, patient Advocacy Groups, are some of the important factors that are fueling the Peritoneal Cancer Market.

Peritoneal Cancer Pipeline Market Barriers
• However, clinical Trial Challenges, high Development Costs, regulatory Hurdles, limited treatment Options and other factors are creating obstacles in the Peritoneal Cancer Market growth.

Scope of Peritoneal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Peritoneal Cancer Companies: AB Science, Zentalis Pharmaceuticals, ImmunoGen, Hoffmann-La Roche, Corcept Therapeutics, Memorial Sloan Kettering Cancer Center, LintonPharm Co.,Ltd., M.D. Anderson Cancer Center, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Kancera AB, Haider Mahdi, RemeGen Co., Ltd., Hansoh BioMedical, OncXerna Theraputics, Inc, and others
• Key Peritoneal Cancer Therapies: Masitinib, Azenosertib, IMGN151, Bevacizumab, Nab-paclitaxel, 131 I-omburtamab, Catumaxomab, Fulvestrant, Bevacizumab, Carboplatin, MORAb-202, KAND567, ZEN003694, RC88, HS-20089, navicixizumab, and others
• Peritoneal Cancer Therapeutic Assessment: Peritoneal Cancer current marketed and Peritoneal Cancer emerging therapies
• Peritoneal Cancer Market Dynamics: Peritoneal Cancer market drivers and Peritoneal Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.